Paper - WANFANG MED ONLINE

You Position: Home > Paper

Genetic association of urokinase-type plasminogen activator gene rs2227564 site polymorphism with sporadic Alzheimer's disease in the Han Chinese population

( views:124, downloads:0 )

Author:: No author available

Journal Title:: Neural Regeneration Research

Issue:: 30

DOI:: 10.3969/j.issn.1673-5374.2012.30.008

Key Word:: Alzheimer's disease;urokinase plasminogen activator;polymorphism;genetic testing;Han Chinese population;neural regeneration

Abstract： A missense C/T polymorphism in exon 6 (the NCBI rsID is rs2227564) of the urokinase-type plasminogen activator gene has been identified as a possible hot spot for Alzheimer's disease risk.The present study analyzed urokinase-type plasminogen gene polymorphisms of rs2227564 with sporadic Alzheimer's disease by PCR-restriction fragment length polymorphism.Results showed that CC,CT and TT genotype distribution frequencies had significant differences between sporadic Alzheimer's disease patients and healthy controls.In-depth analysis of the association between urokinase-type plasminogen gene rs2227564 polymorphisms and sporadic Alzheimer's disease indicated that people with the C-positive genotype CC + CT were at a higher risk for developing sporadic Alzheimer's disease.These results support the contribution of the polymorphisms of rs2227564 in the urokinase-type plasminogen gene to the pathogenesis of sporadic Alzheimer's disease in the Han Chinese population.

Reference

[1]Jankun J,Skrzypczak Jankun E.Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity?[J].2010,26(1).
[2]I V, Kurochkin,S, Goto.Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme.[J].1994,345.
[3]Blomqvist ME,Bogdanovic N,Katzov H,etc.Towards compendia of negative genetic association studies: an example for Alzheimer disease.[J].2006,119(1).
[4]Degen JL.Hemostatic factors and inflammatory disease.[J].1999,82(2).
[5]Exley C,Korchazhkina OV.Plasmin cleaves Abeta42 in vitro and prevents its aggregation into beta-pleated sheet structures.[J].2001,12(13).
[6]Ozturk A,DeKosky ST,Minster RL,etc.Association of tagSNPs in the urokinase-plasminogen activator (PLAU) gene with Alzheimer's disease and associated quantitative traits.[J].2007,144(1).
[7]N, Blin,D W, Stafford.A general method for isolation of high molecular weight DNA from eukaryotes.[J].1976,3.
[8]Fabbro S,Seeds NW.Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.[J].2009,109(2).
[9]T C, Saido.Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid.[J].1900,19.
[10]Zamolodchikov,D.,Strickland,S..Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin[J].2012,119(14).
[11]Scheff S,Price D,Tucker HM,etc.The plasmin system is induced by and degrades amyloid-beta aggregates.[J].2000,20(11).
[12]Podlisny MB,Selkoe DJ.Deciphering the genetic basis of Alzheimer's disease.[J].2002,3(0).
[13]Gebbink MF.Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis.[J].2011,9(Suppl.1).
[14]M, Yoshimoto,Y, Ushiyama,M, Sakai,etc.Characterization of single chain urokinase-type plasminogen activator with a novel amino-acid substitution in the kringle structure.[J].1996,1293(1).
[15]Schaller, J.,Gerber, S.S..The plasmin-antiplasmin system: Structural and functional aspects[J].2011,68(5).
[16]Kosik, K.S..Alzheimer's disease: A cell biological perspective. (cover story)[J].1992,256(5058).
[17]Pesaresi M,Prato F,Batelli S,etc.The urokinase-type plasminogen activator polymorphism PLAU_1 is a risk factor for APOE-epsilon4 non-carriers in the Italian Alzheimer's disease population and does not affect the plasma Abeta(1-42) level.[J].2007,25(3).
[18]G, McKhann,D, Drachman,M, Folstein,etc.Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.[J].1984,34.
[19]Mueller JC,Archetti S,Wagenpfeil S,etc.A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease.[J].2006,15(16).
[20]D A, Evans,L A, Beckett,T S, Field,etc.Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons.[J].1997,277.
[21]Alberici A,Hock C,Nitsch RM,etc.Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2.[J].2003,4(4).
[22]Kihiko Ehman M,Petersen RC,Younkin SG,etc.Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene.[J].2005,14(3).
[23]Tucker HM,Estus S,Kihiko Ehmann M.Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen.[J].2002,70(2).
[24]Hofman A,Breteler MM,Slooter AJ,etc.Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study.[J].1998,55(7).
[25]Love,S.,Barker,R.,Kehoe,P.G..Activators and inhibitors of the plasminogen system in Alzheimer's disease[J].2012,16(4).
[26]Haines JL,Pericak-Vance MA,Martin ER,etc.Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis.[J].2008,32(3).
[27]H. H. Petersen,P. A. Andreasen,R. Egelund.The plasminogen activation system in tumor growth, invasion, and metastasis[J].2000,57(1).
[28]Gerard C,Westaway D,Iwata N,etc.Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.[J].2002,43(1).
[29]Van Nostrand-WE,Porter M.Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.[J].1999,38(35).
[30]Tracy J,Wollmer MA,Huynh KD,etc.No association of a non-synonymous PLAU polymorphism with Alzheimer's disease and disease-related traits.[J].2005,132(1).
[31]S, Howell,J, Nalbantoglu,P, Crine.Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism.[J].1995,16(4).
[32]Kehoe PG,Baig S,Miners JS,etc.Abeta-degrading enzymes in Alzheimer's disease.[J].2008,18(2).
[33]Jacobsen, JS,Comery, TA,Martone, RL,etc.Enhanced clearance of A beta in brain by sustaining the plasmin proteolysis cascade[J].2008,105(25).
[34]Murphy R,Eden G,Britto M,etc.The urokinase receptor in the central nervous system.[J].2011,10(2).
[35]Liu RM,Akhter H,Li L,etc.Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease.[J].2011,26(4).
[36]Iwata N,Saido TC,Higuchi M.Metabolism of amyloid-beta peptide and Alzheimer's disease.[J].2005,108(2).
[37]Panza F,Seripa D,Franceschi M.Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer's disease.[J].2009,8(3).